



# Involvement of Rac1 in Activation of Multicomponent Nox1- and Nox3-Based NADPH Oxidases

Ueyama, Takehiko

Geiszt, Miklos

Leto, Thomas L.

---

(Citation)

Molecular and Cellular Biology, 26(6):2160-2174

(Issue Date)

2006-03

(Resource Type)

journal article

(Version)

Version of Record

(URL)

<https://hdl.handle.net/20.500.14094/90000354>



## Involvement of Rac1 in Activation of Multicomponent Nox1- and Nox3-Based NADPH Oxidases

Takehiko Ueyama,<sup>1\*</sup> Miklós Geiszt,<sup>2</sup> and Thomas L. Leto<sup>1\*</sup>

*The Molecular Defenses Section, Laboratory of Host Defenses, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892,<sup>1</sup> and Department of Physiology, Semmelweis University, Faculty of Medicine, P.O. Box 259, H-1444 Budapest, Hungary<sup>2</sup>*

Received 17 June 2005/Returned for modification 14 July 2005/Accepted 30 December 2005

**Several Nox family NADPH oxidases function as multicomponent enzyme systems. We explored determinants of assembly of the multicomponent oxidases Nox1 and Nox3 and examined the involvement of Rac1 in their regulation. Both enzymes are supported by p47<sup>phox</sup> and p67<sup>phox</sup> or homologous regulators called Noxo1 and Noxa1, although Nox3 is less dependent on these cofactors for activity. Plasma membrane targeting of Noxa1 depends on Noxo1, through tail-to-tail interactions between these proteins. Noxa1 can support Nox1 without Noxo1, when targeted to the plasma membrane by fusing membrane-binding sequences from Rac1 (amino acids 183 to 192) to the C terminus of Noxa1. However, membrane targeting of Noxa1 is not sufficient for activation of Nox1. Both the Noxo1-independent and -dependent Nox1 systems involve Rac1, since they are affected by Rac1 mutants or Noxa1 mutants defective in Rac binding or short interfering RNA-mediated Rac1 silencing. Nox1 or Nox3 expression promotes p22<sup>phox</sup> transport to the plasma membrane, and both oxidases are inhibited by mutations in the p22<sup>phox</sup> binding sites (SH3 domains) of the Nox organizers (p47<sup>phox</sup> or Noxo1). Regulation of Nox3 by Rac1 was also evident from the effects of mutant Rac1 or mutant Nox3 activators (p67<sup>phox</sup> or Noxa1) or Rac1 silencing. In the absence of Nox organizers, the Nox activators (p67<sup>phox</sup> or Noxa1) colocalize with Rac1 within ruffling membranes, independently of their ability to bind Rac1. Thus, Rac1 regulates both oxidases through the Nox activators, although it does not appear to direct the subcellular localization of these activators.**

Reactive oxygen species (ROS) are produced in phagocytic cells by NADPH oxidase, a complex that transports electrons across membranes and generates superoxide anion from molecular oxygen. This enzyme is assembled from a membrane-spanning flavocytochrome *b*<sub>558</sub>, composed of Nox2 (also called gp91<sup>phox</sup>) and p22<sup>phox</sup> and four cytosolic factors (p47<sup>phox</sup>, p67<sup>phox</sup>, p40<sup>phox</sup>, and Rac) that associate with the flavocytochrome to form an active enzyme (40). Chronic granulomatous disease, characterized by defective microbial killing by phagocytic cells, is caused by defects or deficiencies in any one of four oxidase components: Nox2, p22<sup>phox</sup>, p47<sup>phox</sup>, or p67<sup>phox</sup> (40). An essential role for Rac1 or Rac2 in NADPH oxidase activation was also identified in cell-free reconstitution studies (1, 32). This role was later confirmed in an oxidase-deficient patient who expressed mutant Rac2 (5) and in mice rendered genetically deficient in Rac2 (48). Recently, several novel homologs of the catalytic, electron carrier component of NADPH oxidase (gp91<sup>phox</sup> or Nox2) have been described in a variety of nonphagocytic cells (22, 36). This new NADPH oxidase or Nox family encompasses seven enzymes identified in humans: Nox1, Nox2 (gp91<sup>phox</sup>), Nox3, Nox4, Nox5, Duox1, and Duox2. Nox1 and Nox3 are the closest homologs of Nox2 in terms of structure and function. Nox1 is detected in abundance in the

colon and at lower levels in uterus, prostate, and vascular smooth muscle and endothelial cells (2, 50). Although originally suggested to function as a promitogenic oxidase, Nox1 more likely functions as a host defense oxidase (19, 29), like Nox2, and may have physiological and pathological roles in vascular tissue (2, 38). Nox3 mRNA was detected in several fetal tissues by reverse transcription-PCR, including kidney, liver, lung, and spleen (12, 31). Recently, a unique role for this oxidase was revealed within the inner ear (vestibular system) by positional cloning studies that mapped genetic lesions causing the head tilt (*het*) phenotype in mice (45). Mice with Nox3 mutations exhibit impaired otoconial morphogenesis and defects in perception of gravity and balance. Subsequently, Nox3 expression was detected in the cochlear system, and it was suggested that Nox3-derived ROS could contribute to hearing loss and balance problems (8).

Both the Nox1 and Nox3 oxidases appear to function as multicomponent enzymes similar to the phox (Nox2-based) system (7, 8, 14, 15, 21, 22, 29, 54, 55). Nox1 expressed alone produces little superoxide, although its activity is dramatically enhanced in the presence of two cofactors (Noxo1 and Noxa1) that are detected in colon epithelium (7, 21, 54). Noxo1 was proposed to act as a “Nox organizer” based on structural and functional similarities with p47<sup>phox</sup>, which is a multimodular adaptor protein that bridges interactions between the flavocytochrome *b*<sub>558</sub> and p67<sup>phox</sup> by binding to both p22<sup>phox</sup> and p67<sup>phox</sup>. Noxa1 was designated as a “Nox activator” based on its homology to p67<sup>phox</sup>, which binds to Rac1 or Rac2 and promotes electron flow through the flavocytochrome in a GTP-dependent manner (10). The phagocytic oxidase can be reconstituted *in vitro* in the absence of p47<sup>phox</sup>, when p67<sup>phox</sup> and

\* Corresponding author. Mailing address for Thomas L. Leto: NIH, NIAID, Twinbrook II, Room 203, 12441 Parklawn Dr., Bethesda, MD 20892. Phone: (301) 402-5120. Fax: (301) 480-1731. E-mail: tleto@nih.gov. Mailing address for Takehiko Ueyama: Laboratory of Molecular Pharmacology, Biosignal Research Center, Kobe University, 1-1, Rokkodai-cho, Nada-ku, Kobe 657-8501, Japan. Phone: 81-78-803-5962. Fax: 81-78-803-5971. E-mail: tueyama@kobe-u.ac.jp.

Rac1 are provided in excess (18, 34) or when p67<sup>phox</sup> is adapted with the membrane-binding sequences of Rac1, although GTP-bound Rac is still required for activation (3, 23, 24, 42). Noxa1 was shown to bind Rac1 in a GTP-dependent manner (54), although its role as a Nox1 regulator involving Rac1 has not been demonstrated directly. Both the human and murine Nox1 systems (comprising Nox1, Noxo1, and Noxa1) exhibit high constitutive activity, while activity of the human system is significantly enhanced by cellular activation in several cell types (7, 21, 28, 54). Recently, several groups examined involvement of the Nox1 or Nox2 (phox) regulators in Nox3 activity and showed that this enzyme is less subject to the tight cofactor-dependent controlling mechanisms observed with Nox1 or Nox2 (8, 15, 55). Furthermore, there has been no direct evidence for Rac-dependent regulation of Nox3 activity (55).

In this study we examine the multicomponent nature (subcellular targeting, assembly, and activation) of Nox1- and Nox3-based oxidases in transfected cell models by systematically expressing wild-type and mutated forms of various oxidase components. We present evidence indicating that Nox1 and Nox3 are modulated by Rac1 and that this involves the Rac-binding Nox activators, Noxa1 and p67<sup>phox</sup>. We also show that Noxo1 acts as an adaptor protein targeting Noxa1 to the plasma membrane and that p22<sup>phox</sup> is targeted to the plasma membrane when either Nox1 or Nox3 is coexpressed. Finally, using a plasma membrane-targeted form of Noxa1, we reconstitute Noxo1-independent Nox1 activity, which is critically dependent on Rac1.

## MATERIALS AND METHODS

**Materials.** Diphenyleneiodonium chloride (DPI) and superoxide dismutase (SOD) were purchased from Sigma-Aldrich and EMD Biosciences, respectively. Mouse monoclonal antibodies (Abs) against human Rac1 and  $\beta$ -tubulin were from Upstate Biosciences and Sigma-Aldrich, respectively. Rabbit polyclonal anti-V5 peptide horseradish peroxidase Ab and rabbit polyclonal anti-green fluorescent protein (anti-GFP) Ab were from Invitrogen and Clontech, respectively. Rabbit polyclonal Ab was raised against recombinant glutathione *S*-transferase (GST) fused to full-length mouse Noxa1, produced in *Escherichia coli* using pGEX-4T1 (Amersham Biosciences). Goat polyclonal Abs against human p47<sup>phox</sup> and p67<sup>phox</sup> were described previously (39). Mouse monoclonal Ab against p22<sup>phox</sup> (no. 449) was a kind gift from Dirk Roos (57). Rac1 Validated Stealth RNAi (RNA interference) DuoPak and Stealth RNAi Negative Control Medium GC Duplex were obtained from Invitrogen, and Rac1 Silencer Pre-designed siRNA (short interfering RNA) and Silencer Negative Control no. 1 siRNA were from Ambion.

**Cell culture.** All cell culture reagents were obtained from Invitrogen, unless indicated otherwise. Human HEK293 cells (ATCC) were maintained in Eagle's minimal essential medium containing 10% heat-inactivated fetal bovine serum (FBS; HyClone Laboratories), 1 mM sodium pyruvate, 100  $\mu$ M nonessential amino acids, and antibiotics (100 units/ml penicillin and 100  $\mu$ g/ml streptomycin) at 37°C in 5% CO<sub>2</sub>. CHO-K1 cells (ATCC) were maintained in Ham's F-12 medium containing 10% heat-inactivated FBS and antibiotics at 37°C in 5% CO<sub>2</sub>. HT-29 cells (ATCC) were maintained in McCoy's 5A medium (modified) containing 10% heat-inactivated FBS and antibiotics and grown in 5% CO<sub>2</sub> at 37°C.

**Construction of plasmids.** The pcDNA3.1 plasmids (Invitrogen) containing the complete coding sequence of human Nox1, Nox2, p51<sup>nox</sup> (Noxa1), p47<sup>phox</sup>, p67<sup>phox</sup>, and p22<sup>phox</sup> were described previously (20, 21). The full coding sequence for human Nox3 was amplified by PCR using fetal kidney first-strand cDNA (Stratagene) using specific primers designed from previously reported sequence (GenBank accession number NM\_015718) and cloned into pcDNA3.1. Human p41<sup>nox</sup> (Noxo1 $\beta$ ) in pcDNA3.1 was made by adding codon Lys<sup>50</sup> to Noxo1 $\alpha$  (21) using the QuikChange II XL site-directed mutagenesis kit (Stratagene). Full-length Noxo1 $\beta$  and a C-terminally truncated mutant of Noxo1 $\beta$  (amino acids [aa] 1 to 319) lacking the proline-rich region (PRR; aa 320 to 329) that interacts with the C-terminal SH3 domain of Noxa1 were amplified by PCR, cloned into pcDNA3.1D/V5-His-TOPO (Invitrogen), and designated Noxo1-V5 and Noxo1 ( $\Delta$ PRR)-V5, respectively. Full-length Noxo1 $\beta$  was amplified by PCR and cloned

into the EcoRI and BamHI sites of pEGFP-N1 (Clontech) and designated Noxo1-GFP. We confirmed that Noxo1-GFP supports Nox1 activity in the presence of Noxa1 at levels comparable to those of unfused, native Noxo1 (data not shown) (14). The cDNAs encoding human wild-type Rac1, Rac1(Q61L), Rac1(T17N), and Rac1(G30S) were described previously (35); these cDNAs were amplified by PCR and cloned into pCMV-Myc (Clontech) to express N-terminal, c-Myc epitope-tagged versions of these proteins. Mouse Rac1 in pEGFP-C1 (Clontech) was described previously (56). Human Noxa1 and p67<sup>phox</sup> coding sequences were adapted with the C-terminal, polybasic region of Rac1 (KKRKRR; aa 183 to 188) and isoprenylation "CAAX" motif of Rac1 (CLLL; aa 189 to 192) by PCR amplification (see Fig. 2B and Fig. 9D), using specific reverse primers that provided these sequences, and then cloned into pcDNA3.1; the fused constructs were designated Noxa1(pp) and p67<sup>phox</sup>(pp), respectively. All other indicated amino acid mutations, Noxa1(R103E), Noxa1(pp, R103E), Noxa1(W436R), Noxa1(R103E, W436R), Noxo1(W197R), p67<sup>phox</sup>(R102E), p67<sup>phox</sup>(pp, R102E), and p47<sup>phox</sup>(W193R) in pcDNA3.1 and Noxo1(W197R) in pcDNA3.1D/V5-His-TOPO, were produced using the QuickChange II XL site-directed mutagenesis kit. All modified expression vectors were sequenced to confirm their identities.

**Cell fractionation and immunoblotting.** Cells were sonicated in disruption buffer (44) in the presence of protease inhibitor cocktail (Sigma-Aldrich), and the sonicate was centrifuged for 10 min at 10,000  $\times$  g. The supernatant was further centrifuged for 1 h at 100,000  $\times$  g. The pellet was defined as the membrane fraction, and the supernatant was defined as the cytosolic fraction. Western blotting was performed on proteins transferred to nitrocellulose membranes, preblocked in 5% nonfat dry milk in Tris-buffered saline (TBS) containing 0.03% Triton X-100 (TBST), and probed with primary antibody prepared in TBST at the dilutions indicated: Noxa1, 1:1,000; Rac1, 1:2,000; p47<sup>phox</sup>, 1:2,000; p67<sup>phox</sup>, 1:2,000;  $\beta$ -tubulin, 1:2,000; V5-horseradish peroxidase, 1:5,000; GFP, 1:2,000. Bound antibodies were detected with secondary antibody-peroxidase conjugates using the ECL detection system (Amersham Biosciences). In the case of fractionation studies using synthetic siRNA, suppressed levels of Rac1 protein were confirmed using aliquots of total lysates in each experiment.

**Confocal fluorescence imaging studies.** Cells (HEK293 or CHO-K1) were seeded on 35-mm glass-bottom dishes (MatTek Chambers) and transfected using FuGENE 6 (Roche Applied Science). At 40 to 48 h after the transfection, cells were fixed using 10% formalin in neutral buffered solution (Sigma-Aldrich). After permeabilization with TBS containing 0.3% Triton X-100 for 10 min, the fixed cells were stained for 2 h at room temperature (RT) using each primary antibody (Noxa1, p67<sup>phox</sup>, p22<sup>phox</sup>, or Rac1) at 1:200 dilutions (TBST with 5% bovine serum albumin). Secondary antibody-fluor conjugates (anti-rabbit antibody-Alexa 488 or anti-mouse or anti-goat antibody-Alexa 594; 1:2,000 dilutions) were applied for 0.5 h at RT. Confocal imaging was performed using a TCS-SP2 ABOS confocal laser scanning fluorescence microscope (63 $\times$  oil) (Leica Microsystems GmbH).

**Rac1 activation assay.** Rac1 activation assays were performed using the Rac1 activation assay kit (Upstate Biosciences) according to the manufacturer's suggested protocol. Briefly, cells (HEK293 or CHO-K1) grown in 10-cm dishes were harvested using 500  $\mu$ l of lysis/wash buffer (25 mM HEPES, pH 7.5, 150 mM NaCl, 1% Nonidet P-40, 10 mM MgCl<sub>2</sub>, 1 mM EDTA, 10% glycerol, 1 mM phenylmethylsulfonyl fluoride, and 20  $\mu$ g/ml leupeptin). Cell lysates were centrifuged for 5 min at 3,000  $\times$  g, and the resulting supernatants were mixed with 10  $\mu$ g of GST-PAK1-CRIB conjugated to glutathione-agarose beads and rocked at 4°C for 1 h. For positive and negative control experiments, 100  $\mu$ M GTP $\gamma$ S or 1 mM GDP was added in 500  $\mu$ l of the resulting supernatant described above. After the mixture was rocked for 15 min at RT, the supernatant was mixed with GST-PAK1-CRIB-conjugated glutathione-agarose beads and rocked at 4°C for 30 min. After three washes, the beads were resuspended in Laemmli sample buffer, and the proteins bound to PAK1-CRIB were separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis and probed with Rac1 antibody (Upstate Biosciences).

**Cell transfections and ROS production assays.** Cells were seeded in six-well dishes at 250,000 cells/well (HEK293 cells), 75,000 cells/well (CHO-K1 cells), or 700,000 cells/well (HT-29 cells) for 48 h prior to transfection. Cell transfections were performed in serum-free medium using 6  $\mu$ l of FuGENE 6 prepared in complexes with plasmid DNAs (HEK293 and CHO-K1 cells, total, 2  $\mu$ g/well; 0.5  $\mu$ g of Nox1 or Nox3, plus 0.5  $\mu$ g each of other expression vectors or pcDNA3.1 [control] plasmid; HT-29 cells, 0.5  $\mu$ g each of expression vectors or pcDNA3.1 [control] plasmid without Nox1), using the manufacturer's suggested protocol; in studies expressing mutant products, equal moles of plasmid were used in place of wild type. The cells were fed 5 h posttransfection with complete medium and were assayed 48 h after transfection. Trypsinized cells were assayed for ROS release (with or without activation with 2  $\mu$ g/ml phorbol myristate acetate

[PMA]) by superoxide dismutase-sensitive chemiluminescence methods using the Diogenes reagent (National Diagnostics), as described previously (21). The reagent has 10,000 times greater sensitivity for superoxide than does hydrogen peroxide (J. Kitzler [National Diagnostics], personal communication).

**RNAi-mediated silencing of Rac1.** Rac1-specific short hairpin RNAs (shRNAs) were expressed in pSUPER-gfp, a Neo-resistant vector from Oligoengine (Seattle, WA). Four sequences of 19 or 21 nucleotides in length specific for human Rac1 cDNA (GenBank accession number NM\_006908) were selected for synthesis of shRNA. Their sequences (5'-ACCGGTGAATCTGGGCTTA-3', 5'-ACACTC CCATCATCCTAGT-3', 5'-CCTTGTACGCTTTGCTCA-3', and 5'-GCTAAT AAGTGCTTTCTTAG-3'), corresponding to nucleotides relative to the ATG translational initiation site (147 to 165, 320 to 338, 618 to 636, and 1664 to 1684, respectively) were cloned into BglII and HindIII sites of the vector; these vectors were named pSUPER-Rac1-147, pSUPER-Rac1-320, pSUPER-Rac1-618, and pSUPER-Rac1-1664, respectively. The constructs were sequenced to confirm their identities. In the case of RNAi studies using synthetic siRNAs, the following Rac1-specific or negative control RNAs were used: Rac1 Validated Stealth siRNA-2 (5'-AGGGUCUAGCCAUGGCUAAGGAGAU-3'), Stealth RNAi Negative Control Medium GC, Rac1 Silencer Pre-designed siRNA (siRNA identification: 214526, GCCACUACAACAGAAUUUU), and Silencer Negative Control no. 1 siRNA.

For ROS production assays, HEK293 cell transfections were performed as described above, using 0.1  $\mu$ g of Nox1 or Nox3, plus 50 ng each of other regulator plasmids, and 2.0  $\mu$ g of pSUPER-Rac1 or pSUPER-gfp (control) plasmid. In the case of Noxa1(pp), 0.2  $\mu$ g of Nox1 plus 0.1  $\mu$ g of Noxa1(pp) and 1.7  $\mu$ g of pSUPER-Rac1 or pSUPER-gfp (control) plasmid were used. For synthetic siRNA experiments, transfections of plasmid plus siRNAs were performed using 5  $\mu$ l of Lipofectamine 2000 and Opti-MEM 1 (Invitrogen), as described above. Suppressed Rac1 protein production was confirmed by immunoblotting, as described above.

**Statistical analysis.** Data are presented as the percentage of the maximally reconstituted oxidase activities observed in the absence of cell stimulation and were expressed as means  $\pm$  standard deviations (SD). For Nox1 experiments, full activity (100%) was defined with Nox1 plus Noxa1 plus Noxa1 coexpression; for Nox3, 100% was defined with Nox3 plus Noxa1; for Nox2, 100% was defined with Nox2 plus p47<sup>phox</sup> plus p67<sup>phox</sup> plus PMA. Mean activities were calculated from at least three independent transfection experiments, where each assay was performed in duplicate.

## RESULTS

**Subcellular localization of the Nox activator, Noxa1, is Noxa1 dependent and Rac1 independent.** Earlier studies have shown that Nox1 activity requires coexpression of two supportive cofactors, Noxa1 and Noxa1, which are homologous to p47<sup>phox</sup> and p67<sup>phox</sup>, respectively (7, 14, 21, 54). The activity of the reconstituted human Nox1 system is significantly enhanced by cell stimulation in several transfected models, including NIH 3T3, HEK293, CHO-K1, Cos-7, and T84 cells (21, 29, 54). Recently, Noxa1 was shown to accumulate on the plasma membrane through PX domain-lipid interactions, even without cell stimulation (14). To explore assembly of the Nox1 system further, we examined the subcellular localization of Noxa1 in relation to Noxa1 in transfected HEK293 cells (Fig. 1A to D). Noxa1 was detected with an antibody raised against recombinant murine Noxa1, which detects Noxa1 as a doublet band around 50 kDa by immunoblotting (Fig. 1E), while Noxa1 subcellular localization was followed with a Noxa1-GFP fusion protein. Noxa1-GFP fluorescence occurs predominantly along the plasma membrane (Fig. 1A), as described earlier (14). The association of Noxa1 with the plasma membrane is dependent on Noxa1 (Fig. 1B), since this localization pattern is disrupted by a Noxa1 SH3 domain mutation (W436R) previously shown to inhibit its interactions with the C-terminal PRR of Noxa1 (54). Furthermore, Noxa1 accumulation along the plasma membrane is not observed in the absence of Noxa1 (Fig. 1C). In this case, Noxa1 is found primarily in the cytosol, although a small portion of Noxa1 is also localized to ruffling membranes (Fig. 1C),

especially on the upper surfaces of cells (data not shown). The association of Noxa1 with ruffling membranes is not disrupted with mutant Noxa1(R103E) (Fig. 1D), which no longer binds to Rac1 (54). These results were confirmed in cell fractionation experiments, in which the Noxa1 plasma membrane-targeting protein, Noxa1-GFP, is detected entirely within the membrane (particulate) fraction, not in the cytosolic (soluble) fraction (Fig. 1E). In contrast, the control unfused GFP protein is detected solely in the cytosolic fraction (Fig. 1F, right). Although a portion of Noxa1 is detected in the membrane fraction, the amount in this fraction is increased significantly by cotransfection of Noxa1-GFP but not mutant Noxa1(W436R)-GFP (Fig. 1E, left). The distribution of Noxa1 between membrane and cytosolic fractions is unaffected by the R103E mutation; by coexpression of the constitutively active form of Rac1, Rac1(Q61L); or by suppressing Rac1 production using two specific Rac1-targeted siRNAs (Fig. 1F and G). These observations demonstrate that Noxa1 can serve as an adaptor protein mediating interactions between Noxa1 and the plasma membrane, similar to the role of p47<sup>phox</sup> in the Nox2 system. In addition, these experiments suggest that Rac1 does not affect the subcellular distribution of Noxa1.

**Rac1 modulates Nox1 through its binding partner Noxa1.** The importance of Noxa1 as a mediator of Noxa1-membrane interactions was then explored in Nox1-reconstituted cells. In the HEK293 cell model, the Diogenes-based luminescence assay of Nox1 activity supported by Noxa1 and Noxa1 coexpression is significantly stimulated by PMA, inhibited by DPI, and completely abolished by extracellular addition of SOD (Fig. 2A). However, Nox1 does not produce significant ROS when expressed alone or in pairwise combinations with Noxa1, Noxa1, or Rac1(Q61L), confirming the previously established model involving both Nox regulators (Fig. 2A). Based on several reports indicating that p47<sup>phox</sup> is dispensable in cell-free reconstitution of the Nox2 system (18, 34), particularly if p67<sup>phox</sup> is adapted with membrane-binding sequences of Rac1 (3, 23, 24, 42), we hypothesized that Noxa1 could support Nox1 activity in the absence of its membrane adaptor partner (Noxa1) if Noxa1 is directly targeted to the plasma membrane. Based on reports showing that the polybasic amino acids of Rac1 (KKRK; aa 183 to 188) together with the "CAAX" isoprenylation motif (CLLL; aa 189 to 192) can target proteins to the plasma membrane (16, 56), we constructed a plasma membrane-targeted form of Noxa1 involving a C-terminal fusion with these human Rac1 sequences (Fig. 2B). As shown in Fig. 2C, both immunofluorescence and subcellular fractionation experiments confirmed that this modified form of Noxa1 [Noxa1(pp)] is efficiently targeted to the plasma membrane. Noxa1(pp) supports low but detectable levels of ROS release in Nox1-expressing cells in the absence of Noxa1, although cotransfection of Noxa1(pp) along with Rac1(Q61L) dramatically enhances ROS production by Nox1 (Fig. 2A).

To characterize further the activation of Nox1 supported by Noxa1 in the absence of Noxa1, we examined the effects of Noxa1(R103E) and Rac1 mutants. As shown in Fig. 2A, Noxa1 alone does not support detectable Nox1 activity; however, cotransfection of Noxa1 and Rac1(Q61L) does (Fig. 2D). This activity was completely abolished by the Noxa1(R103E) mutation that disrupts Rac1 binding. Noxa1 and Noxa1(pp) together support activity comparable to levels observed with the wild-type






FIG. 1. Nox1-dependent and Rac1-independent subcellular localization of Noxa1 in HEK293 cells. **A**, Noxo1-GFP is detected predominantly along the plasma membrane. Coexpressed Noxa1 colocalizes with Noxo1 along the plasma membrane. **B**, The association of Noxa1 with the plasma membrane is disrupted by an SH3 domain mutation (W436R) that was shown to disrupt its interaction with the C-terminal, proline-rich region of Noxo1. **C**, Noxa1 expressed alone is localized primarily in the cytosol, although some Noxa1 accumulates at ruffling membranes (arrow). **D**, Localization of Noxa1 at ruffling membranes is not affected by a mutation [Noxa1(R103E)] that disrupts its interaction with Rac1. **E**, The Noxa1 antibody detects transfected Noxa1 as a doublet band around 50 kDa. Wild-type Noxa1 is detected in both cytosol and membrane fractions, consistent with fluorescence imaging. Membrane-associated Noxa1 increases by coexpression of Noxo1-GFP but not Noxa1(W436R)-GFP. Plasma membrane localizing protein, Noxo1-GFP, is detected predominantly in the membrane fraction. **F**, The fractionation of Noxa1 is not affected by a Noxa1 mutation at R103E or coexpression of Rac1(Q61L). Right, cytosolic (unfused) GFP is detected predominantly in the cytosol fraction. **G**, Fractionation of Noxa1 is not affected by two Rac1-suppressing siRNAs (Stealth and Silencer). Immunoblotting of total lysates confirms effective suppression of endogenous Rac1 by these siRNAs. no siRNA, transfection without siRNA. Bar, 10  $\mu$ m. Similar protein loading is confirmed by  $\beta$ -tubulin blotting. Similar results were obtained in four (A, B, C, D, and F) or three (E and G) independent experiments.

proteins, although these proteins show a lower PMA-enhanced component (Fig. 2D). Nox1 activity, supported by Noxa1(pp) alone, is also completely abolished with the Noxa1(pp, R103E) mutant. Nox1 activity reconstituted by Noxa1(pp) and Rac1 (Q61L) is significantly reduced with the Noxa1(pp, R103E) mutant. Finally, no activity is detected by substitution with Noxa1(pp, R103E) combined with Rac1(G30S) (Fig. 2D). Thus, our observations demonstrate that Rac1 can modulate Nox1 through interactions with its binding partner, Noxa1. These experiments reveal close functional parallels in the assembly of Nox1- and Nox2-based oxidases, since Rac1 can modulate both systems through activator proteins (Noxa1 or p67<sup>phox</sup>), which in turn require critical adaptor or organizer proteins (Noxo1 or p47<sup>phox</sup>) to link them to the plasma membrane oxidase complex. Our findings on the contribution of Rac1 to Nox1 activation supported by the membrane-targeted form of Noxa1 [Noxa1(pp)] are analogous to

observations on Nox2 reconstitution by similar, membrane-binding forms of p67<sup>phox</sup> (3, 23); targeting of p67<sup>phox</sup> fusion proteins containing the C-terminal, membrane-binding sequence of Rac1 was not sufficient to support Nox2 in vitro, and addition of the Rac1-GTP moiety is required for full activation.

**Rac1 regulates the fully reconstituted Nox1 system.** To explore further the involvement of Rac1 in the fully reconstituted system comprising Nox1, Noxo1, and Noxa1, we examined two transfected models, HEK293 and CHO-K1 cells. In the HEK293 cell model, neither the defective effector site mutant, Rac1(G30S), nor the constitutively active mutant, Rac1(Q61L), significantly affects Nox1 activity when reconstituted with both Noxo1 and Noxa1 (Fig. 3A). However, in the reconstituted CHO-K1 cell model, Rac1(G30S) shows dominant-negative effects on both basal and PMA-stimulated Nox1 activities (Fig. 3B). Furthermore, Rac1(Q61L) has an enhancing effect on






FIG. 3. Rac1 involvement in the fully activated Nox1 system. A. Neither Rac1(G30S) nor Rac1(Q61L) affects Nox1 activity in the HEK293 cell model. Data are from at least three independent transfection experiments. B. Rac1(G30S) inhibits both basal and PMA-stimulated Nox1 activity in transfected CHO-K1 cells, while Rac1(Q61L) enhances basal activity. Data represent means  $\pm$  SD of at least three independent transfection experiments. (\*,  $P < 0.05$ , compared with no Rac1 transfection [pcDNA3.1]). C. Western blotting of CHO-K1 cell lysates detects both the endogenous and Myc-tagged Rac1 proteins. Comparable protein loading is confirmed by  $\beta$ -tubulin blotting. D. Rac1(G30S) inhibits Nox2 activity in transfected HEK293 and CHO-K1 cells, while Rac1(T17N) inhibits Nox2 only in CHO-K1 cells. Data represent means  $\pm$  SD of at least three independent transfection experiments. (\*,  $P < 0.05$ , compared with no Rac1 transfection [pcDNA3.1]). Western blotting (top panels) detects endogenous and the mutant Myc-tagged Rac1 proteins. E. Immunofluorescence detection of endogenous Rac1 in HEK293 cells reveals significant Rac1 accumulation along the plasma membrane, while Rac1 is localized primarily to the cytosol in CHO-K1 cells. Bar, 10  $\mu$ m. F. Rac1 activation assay detects activated endogenous Rac1 (GTP bound) in unstimulated HEK293 cells but not in CHO-K1 cells. Similar results were obtained in two independent experiments.

pSUPER-Rac1-681, and pSUPER-Rac1-1664 significantly reduce detectable levels of endogenous Rac1 protein, while pSUPER-Rac1-320 has no apparent effect (Fig. 4A). These observations correlate with significant inhibition of Nox1 activity by the effective Rac1-targeting vectors (Fig. 4B). In particular, the most potent Rac1-suppressing vector, pSUPER-Rac1-681, strongly inhibits ROS production reconstituted by Nox1 and Noxa1(pp) ( $12.9\% \pm 3.3\%$  of control activity) (Fig. 4B), a result consistent with data showing that Nox1 activity supported by Noxa1(pp) is completely abolished by Noxa1(pp, R103E) (Fig. 2C). In addition, pSUPER-Rac1-681 significantly reduces the activity of Nox1 supported by

Noxo1 and Noxa1 together ( $42.6\% \pm 4.8\%$  of control). These results suggest that Rac1 supports the fully reconstituted Nox1 system and indicate that, in the absence of Noxo1, the membrane-targeted form of Noxa1 [Noxa1(pp)] is even more dependent on Rac1, since Noxa1(pp) does not support significant ROS production when endogenous Rac1 levels are suppressed. Thus, it appears that activation of both the Nox1 and Nox2 systems requires not only membrane targeting of the Nox activators (Noxa1 or p67<sup>phox</sup>) but also interaction with Rac.

The inhibition of Nox1 activity by Rac1 silencing was also confirmed by the dose-dependent effects of synthetic siRNA










FIG. 5. Disruption of the fully activated Nox1 system by mutations affecting interactions with Rac1, Noxo1, Noxa1, and p22<sup>phox</sup>. A. The fully activated Nox1 system, supported by Noxo1 and Noxa1, is only partially affected by Noxa1(R103E), Noxa1(W436R), or Noxo1(ΔPRR) mutations, which disrupt interactions with Rac1, Noxo1, or Noxa1, respectively. Combined disruption of Noxa1-Rac1 and Noxo1-Noxa1 interactions completely inhibits the Nox1 system, as does a disruption of the Noxo1-p22<sup>phox</sup> interaction. Data are from at least three independent transfection experiments. B. Schematic representation of sites that effectively disrupt Nox1 activity, involving mutations in Noxa1 (left) or Noxo1 (right). The panel is adapted from reference 22. C. Western blotting of HEK293 cell lysates confirms comparable expression of Noxo1-V5 mutants. D. Western blotting confirms comparable expression of Noxa1 mutants. Lower (control) panels confirm comparable protein loading by β-tubulin blotting.

transfection, where the complete Nox1 system is significantly inhibited ( $44.2\% \pm 4.2\%$  or  $41.8\% \pm 5.4\%$  of control values) by Rac1 Validated Stealth siRNA or Rac1 Pre-designed Silencer siRNA, respectively (Fig. 4C). The specificity of these Rac1 silencing effects was demonstrated by complete restoration of Nox1 activity inhibited by Rac1 Silencer siRNA (targeted to the 3' untranslated region of mRNA of human Rac1) following transfection of wild-type human Rac1 cDNA (Fig. 4C). To demonstrate involvement of Rac1 in oxidase activity of colon epithelial cells, we examined the effects of mutant Rac1 and Rac1 siRNA in HT-29 cells, which express endogenous Nox1 (19, 20). Cotransfection of these cells with Noxo1 and Noxa1 significantly enhances basal ROS production, which is inhibited by DPI (Fig. 4D). This activity is enhanced further by Rac1(Q61L) (Fig. 4D). Furthermore, ROS production enhanced by Noxo1 and Noxa1 is significantly inhibited by Rac1




FIG. 6. Nox1- and Nox3-dependent targeting of p22<sup>phox</sup> to the plasma membrane. A and B. Immunofluorescence imaging of endogenous (A) and transfected (B) p22<sup>phox</sup> in HEK293 cells, showing reticular cytosolic and nuclear membrane (arrows) staining patterns. C. Transfection of Nox1 results in a redistribution of endogenous p22<sup>phox</sup> to the plasma membrane. D. A similar redistribution of p22<sup>phox</sup> occurs in Nox3-transfected cells. \*, untransfected cells showing primarily cytosolic staining patterns and overall weaker staining.

Validated Stealth siRNA (targeted to the coding region of mRNA of human Rac1) and is restored by reintroduction of wild-type mouse Rac1, which differs within the targeted human sequence by 4 nucleotides (Fig. 4D). Finally, we validated our Rac1 silencing approach used in these experiments by demonstrating that both the specific vector-based and synthetic siRNAs are also effective inhibitors of the Nox2 system reconstituted in the HEK293 cell model (Fig. 4F). These observations on the involvement of Rac1 in Nox1 activity in the three transfected models confirm and extend the observations of Kawahara et al., who showed restoration of Ly294002-inhibited ROS production in guinea pig gastric pit cells by overexpressing an active mutant of Rac1 (28).

**Nox1 is tightly controlled by multiple interactions involving Noxo1, Noxa1, Rac1, and p22<sup>phox</sup>.** We then studied the assembly and activation of the entire Nox1 system by examining the effects of disrupting various protein-protein interactions within this complex (Fig. 5A). Basal Nox1 activity, reconstituted by Noxo1 and Noxa1, was reduced when the Rac1-binding mutant, Noxa1(R103E), was substituted for wild-type Noxa1, although the activity was still PMA stimulated. Also, the replacement of Noxa1 with the defective Noxo1-binding mutant, Noxa1(W436R), reduces the activity of Nox1, and the activity is still PMA stimulated. The effect of this mutant was confirmed further by expression of the complementary, C-terminal deletion mutant of Noxo1, Noxo1(ΔPRR). However, Nox1 activity supported by Noxo1 and Noxa1 was effectively abolished by the combined Noxa1 mutant Noxa1(R103E, W436R), by the complementary mutants Noxo1(ΔPRR) and Noxa1(R103E),




FIG. 7. Nox3 activity supported by Noxa1 or p67<sup>phox</sup> is Rac1 dependent. A and B. Reconstitution of Nox3 activity with Nox proteins (Noxa1 or Noxo1) in HEK293 and CHO-K1 cells. Noxa1-supported activity is abolished by the SH3 domain (p22<sup>phox</sup> binding site) mutation. Noxa1-supported activity is enhanced by Rac1(Q61L) and abolished by the Rac1 binding site mutation (R103E). Nox3 activity supported by membrane-targeted Noxa1 is inhibited by the R103E mutation. Data are from at least three independent transfection experiments. C and D. Reconstitution of Nox3 activity with phox proteins in HEK293 and CHO-K1 cells. The p47<sup>phox</sup>-supported Nox3 activity is inhibited by the p22<sup>phox</sup> binding site mutation (W193R), while Nox3 activity supported by p67<sup>phox</sup> (wild-type and membrane-targeted forms) is inhibited by the Rac1 binding site mutation. Data are from at least three independent transfection experiments. E. Western blotting of HEK293 cell lysates detects comparable levels of p47<sup>phox</sup> (left) and p67<sup>phox</sup> (right) mutant proteins. Comparable protein loading is confirmed by  $\beta$ -tubulin blotting.

or by the substitution of Noxo1(W197R) for Noxa1. Noxo1 (W197R) is the homologous point mutant of p47<sup>phox</sup>(W193R) that disrupts the interaction between the SH3 domain of p47<sup>phox</sup> and its PRR target site in p22<sup>phox</sup> (17, 51). Thus, the Nox1 system is effectively inhibited either (i) by disruption of the interactions of Noxa1 with both of its partners, Noxo1 and Rac1, thereby blocking access of Noxa1 to Nox1; or (ii) by disruption of the interaction between Noxo1 and p22<sup>phox</sup>, thereby preventing the Noxo1-Noxa1 complex from interacting with the Nox1-p22<sup>phox</sup> complex on the plasma membrane (Fig. 5B). Together, these results demonstrate that full activation of the Nox1 system involves interactions between multiple com-

ponents (Nox1, Noxo1, Noxa1, Rac1, and p22<sup>phox</sup>) that are functionally analogous to all of the critical components of the phagocytic (Nox2) system.

To demonstrate further p22<sup>phox</sup> involvement in the assembly of the Nox1 system, we examined the subcellular localization of p22<sup>phox</sup> in transfected cells. Endogenous p22<sup>phox</sup> detected in HEK293 cells by confocal immunofluorescence microscopy has a reticular intracellular and perinuclear staining pattern (Fig. 6A), and transfected p22<sup>phox</sup> displays a staining pattern similar to that of endogenous p22<sup>phox</sup> (Fig. 6B). Interestingly, Nox1 cotransfection results in dramatic rearrangements of the endogenous p22<sup>phox</sup> staining pattern, leading to significant ac-

cumulation of p22<sup>phox</sup> on the plasma membrane (Fig. 6C). These observations support the idea that Nox1 is stabilized through its association with p22<sup>phox</sup> and that the two chains are transported together to the plasma membrane, where they provide a docking site for the Noxo1-Noxa1 complex. Thus, the activated enzyme would release ROS extracellularly, as is evident from the efficient scavenging effects of exogenously added SOD (Fig. 2A).

**Rac1 is involved in the Nox3 system.** Nox3 also appears to function as a multicomponent system involving p22<sup>phox</sup> and either the Nox or phox supportive cofactors (8, 15, 55). We examined assembly and activation mechanisms of the Nox3 system with a focus on potential involvement of Rac1. As shown in Fig. 6D, transfection of Nox3 in HEK293 cells results in p22<sup>phox</sup> transport to the plasma membrane, as observed with Nox1. Taken together with results showing that Nox3 activity is completely abolished by exogenous SOD (Fig. 7A and B), the Nox3 system appears to release ROS into the extracellular medium, like the Nox1 system.

The physiologically relevant partners of Nox3 have not been clarified; therefore, we examined Nox3 activation using both Nox and phox supportive cofactors in both transfected cell models (Fig. 7). Consistent with previous work (8, 15, 55), transfected Nox3 exhibits detectable activity in the absence of any cotransfected organizer or activator protein. Interestingly, the activity of Nox3 alone was enhanced by Rac1(Q61L). Nox3 activity is maximally enhanced by cotransfection of Noxo1 alone and thus was used as a reference for comparing activities of all other Nox3 partners tested in the HEK293 and CHO-K1 cell models (Fig. 7A and B). This activity is effectively abolished by substitution of Noxo1(W197R) for Noxo1, suggesting that the Noxo1-p22<sup>phox</sup> interaction is critical for Nox3 activity supported by Noxo1. The combined expression of Noxa1 along with Noxo1 results in lower Nox3 activity than that supported by Noxo1 alone. This is consistent with recent findings by others (55), suggesting that Noxo1 and Noxa1 together are not optimally suited as partners of Nox3 or act together to down-regulate Nox3. Noxa1 alone supported low levels of Nox3 activity, but Rac1(Q61L) enhanced this activity. Nox3 activity supported by Noxa1(pp) was higher than that supported by Noxa1 or Noxa1 and Rac1(Q61L). The Nox3 activity supported by Noxa1 or Noxa1(pp) is dramatically decreased by the defective Rac-binding mutants (R103E) of these proteins. Thus, Nox3 activity appears to involve participation of both Rac1 and p22<sup>phox</sup> interactions, although Nox3 is not subject to the same strict requirements for both Nox organizer and activator proteins that are observed with Nox1.

The Nox3 activity supported by phox regulators also appears to involve both p22<sup>phox</sup> and Rac1 interactions. Surprisingly, the activities of Nox3 supported by p47<sup>phox</sup> and p67<sup>phox</sup> together are not significantly responsive to PMA, in both the transfected HEK293 and CHO-K1 cell models (Fig. 7C and D). These are higher than those supported by Noxo1 alone. The activity of these systems is not dramatically inhibited by expression of the p47<sup>phox</sup>(W193R) mutant, which disrupts the interaction between the SH3 domain of p47<sup>phox</sup> and its PRR target site in p22<sup>phox</sup> (17, 51). Nox3 is supported at low levels by p47<sup>phox</sup> alone in both cell models; this activity is enhanced by PMA and abolished by replacement with the p47<sup>phox</sup>(W193R) mutant. Nox3 is activated to a significant extent by p67<sup>phox</sup> alone, and




FIG. 8. Suppression of Nox3 activity by Rac1-specific siRNAs in HEK293 cells. A. Nox3 basal activity, as well as Nox3 activity supported by Noxa1, p67<sup>phox</sup>, or p67<sup>phox</sup> and p47<sup>phox</sup>, is significantly inhibited by pSUPER-Rac1-147, pSUPER-Rac1-681, or pSUPER-Rac1-1664 (vector-based RNAi). Data represent means  $\pm$  SD of at least three independent transfection experiments [\* $P$  < 0.05, compared with pSUPER (vector)]. B. Nox3 activity supported by p67<sup>phox</sup> and p47<sup>phox</sup> is significantly inhibited by Rac1 Stealth siRNA or Rac1 Silencer siRNA and restored by reintroduction of wild-type human Rac1 (0.5  $\mu$ g). Right panel, Western blotting confirms significant knockdown of endogenous Rac1 protein by Rac1 Silencer siRNA and production of Myc-tagged wild-type human Rac1 (lysates are from the same number of cells). Data represent means  $\pm$  SD of at least three independent transfection experiments (\* $P$  < 0.05, compared with no siRNA and negative-control siRNA).

the activity supported by p67<sup>phox</sup>(pp) alone reaches almost the same level as that of the Nox3-p47<sup>phox</sup>-p67<sup>phox</sup> system. Together, these observations suggest that p47<sup>phox</sup> plays a relatively minor role in supporting Nox3, in comparison with p67<sup>phox</sup>. Nox3 activity supported by p67<sup>phox</sup> or p67<sup>phox</sup>(pp) is dramatically reduced by p67<sup>phox</sup>(R102E) or p67<sup>phox</sup>(pp, R102E). Residue Arg102 in p67<sup>phox</sup> forms direct hydrogen bonds with Rac1, and the mutation to Glu disrupts the ability of p67<sup>phox</sup> to support the Nox2(phox)-based oxidase (33, 37). Expression of Rac1(Q61L) does not result in any further en-



hancing effects on p67<sup>phox</sup> or p67<sup>phox</sup>(pp)-supported Nox3 activity (data not shown). Finally, the activity of Nox3 supported by p47<sup>phox</sup> and p67<sup>phox</sup> is partially inhibited by replacement with the p67<sup>phox</sup>(R102E) mutant and almost completely abolished by coexpression of p47<sup>phox</sup>(W193R) and p67<sup>phox</sup>(R102E). Together, these results provide strong evidence for the involvement of Rac1 in the Nox3 system reconstituted with phox regulators in both transfected models.

To demonstrate further the involvement of Rac1 in the Nox3 system, we used the RNAi method to suppress Rac1 levels in the HEK293 cell model (Fig. 8). Basal Nox3 activity is reduced to 60.2%  $\pm$  9.2% of control levels with Rac1-specific siRNA (pSUPER-Rac1-681). Nox3 activity reconstituted by Noxa1 alone or by p67<sup>phox</sup> alone is reduced to 48.2%  $\pm$  8.0% or 48.6%  $\pm$  3.8%, respectively, with pSUPER-Rac1-681. Finally, the full activity of Nox3 reconstituted by p47<sup>phox</sup> and p67<sup>phox</sup> together is also significantly reduced to 45.6%  $\pm$  5.6% by pSUPER-Rac1-681 (Fig. 8A). These results were confirmed by synthetic siRNA transfection experiments, in which Nox3 activity supported by p47<sup>phox</sup> and p67<sup>phox</sup> is inhibited more than 60% by two different reagents (39.9%  $\pm$  8.2% or 37.8%  $\pm$  5.0% by Rac1 Validated Stealth siRNA or Rac1 Pre-designed Silencer siRNA, respectively) (Fig. 8B). Moreover, the activity inhibited by Silencer siRNA is completely restored by reintroduction of wild-type human Rac1 (Fig. 8B).

To examine in more detail the basis of p67<sup>phox</sup>-supported Nox3 activity, we explored the subcellular localization of p67<sup>phox</sup>. As observed with Noxa1, p67<sup>phox</sup> localizes to membrane ruffles (Fig. 9A), with an appearance that closely resembles that of Rac1, consistent with recent observations in endothelial cells (11); however, this colocalization with Rac1 is not disrupted with Noxa1(R103E) (Fig. 9B). These observations were confirmed in cellular fractionation experiments, which do not detect any changes in p67<sup>phox</sup> distribution between membrane and cytosolic fractions in cells expressing the defective Rac-binding mutant form p67<sup>phox</sup>(R102E) (Fig. 9C, left) or in cells with suppressed Rac1 expression caused by siRNA (Fig. 9C, right). In contrast, p67<sup>phox</sup>(pp) is localized predominately on the plasma membrane (Fig. 9E), consistent with its ability to support higher levels of Nox3 activity in comparison with wild-type p67<sup>phox</sup> (Fig. 7C). These observations suggest that Rac1 does not serve as a determinant in the subcellular localization of p67<sup>phox</sup>.

## DISCUSSION

In this study, we explored determinants of cellular targeting, assembly, and activation of the two closest homologs of the phagocytic (Nox2-based) NADPH oxidase, Nox1 and Nox3, and obtained evidence indicating that both of these multicomponent enzymes are regulated by the small GTPase Rac1. Both enzymes are supported by “activator” and “organizer” components, although their dependence on these regulators differs significantly (7, 8, 15, 21, 54, 55). By systematically expressing wild-type and mutant forms of these components in transfected cell models, we assessed the relative contributions of these regulators and delineated a hierarchy of interactions governing assembly and activation of these novel oxidase complexes.

The molecular mechanisms controlling phagocytic oxidase activity have been studied extensively (6, 40, 43, 53). The importance of multiple, specific protein-protein interactions in




FIG. 9. p67<sup>phox</sup> localizes to ruffling membranes in HEK293 cells. A. p67<sup>phox</sup> is detected in cytosol and ruffling membranes; Rac1 colocalizes with p67<sup>phox</sup> on membrane ruffles. B. p67<sup>phox</sup>(R102E) also colocalizes with Rac1 within ruffling membranes. C. Wild-type and p67<sup>phox</sup>(R102E) are distributed similarly between cytosol and membrane fractions. Right, fractionation of p67<sup>phox</sup> is not affected by two Rac1-specific siRNAs. Immunoblotting of total lysates shows effective knockdown of endogenous Rac1 by the Rac1-specific siRNAs. no siRNA, transfection without siRNA. D. Schematic representation of the p67<sup>phox</sup>(pp) structure. E. Plasma membrane targeting of p67<sup>phox</sup>(pp). Right, fractionation study confirms p67<sup>phox</sup>(pp) targeting to the membrane fraction. Bar, 10  $\mu$ m. Comparable protein loading is confirmed by  $\beta$ -tubulin blotting. Similar results were obtained in four (A, B, C [left], and E [left]), three (C [right]), or two (E [right]) separate experiments.

the assembly of this complex has been appreciated through analysis of a variety of molecular lesions observed in chronic granulomatous disease. For example, both flavocytochrome subunits are needed to stabilize this protein, enable complete posttranslational processing, and direct the mature protein to the plasma membrane (47, 58, 59). The p47<sup>phox</sup> “adaptor” component binds to membrane lipids, is tethered to the cyto-

chrome  $b_{558}$  through direct interactions with  $p22^{phox}$ , and is involved in linking other cytosolic phox proteins to this complex (41, 52). Rac and  $p67^{phox}$  together have more direct roles in regulating electron flow through the flavocytochrome through GTP-dependent interactions (10). The phagocytic enzyme is capable of robust oxidative output, although its activity is effectively suppressed in resting cells as the components of the latent enzyme are maintained in separate compartments. The flavocytochrome is stored within intracellular membranes (27), Rac is maintained in a GDP-bound cytosolic complex dimerized with Rho-GDI (9), and the other phox proteins associate in a separate cytosolic complex in a dephosphorylated state (6, 40, 43). Following cellular activation, these components assemble into the active, membrane-bound complex through distinct, but coordinated, signaling events. The flavocytochrome translocates to specific membrane domains; the cytosolic components are phosphorylated, thereby inducing conformational changes that favor interactions with the cytochrome  $b_{558}$ ; and Rac dissociates from RhoGDI and translocates independently to the membrane following exchange of GDP for GTP (26, 60). Extensive studies of cell-free oxidase reconstitution suggest that Rac can serve two functions in supporting the Nox2 complex: tethering  $p67^{phox}$  to the membrane and inducing conformational changes in  $p67^{phox}$  that promote oxidase activation (3, 23, 24, 49). Our current observations in transfected cell models indicate that Rac1 also functions in supporting Nox1- and Nox3-based oxidase systems through interactions with the "activator" components; however, we did not obtain evidence supporting the proposal that Rac1 serves as a carrier protein that directs the subcellular location of these activators (Fig. 1F and G and Fig. 9C).

Our studies, together with other recent findings, indicate that a similar hierarchy of interactions occurs in the reconstituted Nox1 system. Nox1 and  $p22^{phox}$  appear to associate and function as a heterodimeric complex, in that the coexpression of both chains leads to enhanced oxidative output and increased stabilization of both subunits (4, 30, 54). These chains form a physical complex, as assessed by colocalization, coimmunoprecipitation, and fluorescence resonance energy transfer (4, 25, 30). We have now shown that Nox1 coexpression enables specific targeting of  $p22^{phox}$  to the plasma membrane (Fig. 6), along with release of ROS into the extracellular compartment. Noxa1 is also targeted to the plasma membrane through tail-to-tail interactions with Noxo1 (Fig. 1), analogous to the functional relationship between  $p67^{phox}$  and  $p47^{phox}$ . However, Noxo1 membrane interactions do not play the same critical role as  $p47^{phox}$  in regulating assembly, since Noxo1 is detected on the membrane even in the absence of cellular activation (14). The association of Noxo1 with the membrane was attributed primarily to constitutive PX domain-membrane lipid interactions (14), which occur in the absence of sequence homologous to the phosphorylated autoinhibitory domain of  $p47^{phox}$ . Nonetheless, we and others demonstrated the importance of the Noxo1- $p22^{phox}$  interaction through the inhibitory effects of mutations that block this interaction on Nox1 activity (Fig. 5) (30, 54). Noxo1 participation in the Nox1 system appears to be dispensable when Noxa1 is adapted with sequence that can otherwise target this protein to the membrane, since this form of Noxa1 [Noxa1(pp)] can effectively support oxidase activity in the absence of Noxo1. Previous

cell-free reconstitution studies have shown that the  $p47^{phox}$  component is also dispensable in the Nox2 system, when  $p67^{phox}$  and Rac are provided in excess (18, 34) or when fusion proteins of  $p67^{phox}$  are constructed that anchor  $p67^{phox}$  to membrane (3, 23, 24, 42). Thus, like  $p47^{phox}$ , Noxo1 appears to function principally as an adaptor that bridges interactions, in this case between Noxa1 and the membrane (lipid and  $p22^{phox}$ ). Finally, Noxa1 functions as a Rac1-GTP-dependent modulator of Nox1 activity, analogous to the role of  $p67^{phox}$  in Rac-dependent regulation of Nox2 activity (3, 10, 23, 24, 42).

We obtained three independent lines of evidence indicating involvement of Rac1 in Nox1 regulation: (i) mutant forms of Noxa1 defective in Rac1 binding support lower levels of Nox1 activity than do wild-type Noxa1, (ii) overexpressed mutant forms of Rac1 affect Nox1 activity, and (iii) siRNA-mediated suppression of Rac1 expression results in diminished Nox1 activity, which is restored by wild-type Rac1 overexpression. The participation of Noxa1 and Rac1 as GTP-dependent interacting regulators of Nox1 activity was most evident in the absence of Noxo1. This was particularly clear when the requirement for Noxo1 was partially compensated by Noxa1(pp) (Fig. 2 and 4), which localizes at the plasma membrane but does not support ROS production without interaction with Rac1. Our observations on the Rac1-GTP dependence of Noxa1(pp) (Fig. 2 and 4) are analogous to those of Alloul et al. and Gorzalcany et al. on a  $p67^{phox}$ -Rac1 chimera protein,  $p67^{phox}$  (1-212)-Rac1 (178-192), which binds to the membrane but is unable to support Nox2 activity in vitro in the absence of the Rac1-GTP moiety that interacts with  $p67^{phox}$ ; addition of Rac1-GTP $\gamma$ S or insertion of Rac1 effector moiety to the chimera  $p67^{phox}$  (1-212)-Rac1 (1-192) supports high Nox2 activity even in the absence of  $p47^{phox}$  (3, 23). Analysis of the effects of multiple disrupted interactions (Fig. 5A and B), as well as the effects of Rac1-targeting siRNAs, indicated Rac1 involvement even with the fully reconstituted Nox1 system. Our results implicating Rac1 in Nox1 activation are further supported by recent work suggesting Rac1 participation in lipopolysaccharide-mediated Nox1 activation in gastric pit cells (28), as well as work suggesting involvement of the Rac1 guanine nucleotide exchange factor beta Pix in Nox1 activation (46), although these studies did not examine the involvement of Noxa1 as the direct effector of Rac1. It is not entirely clear which Nox1 component accounts for PMA-enhanced oxidase activity, although Noxo1 is the least likely candidate. Unlike  $p47^{phox}$ , Noxo1 is membrane bound even without cell stimulation, does not contain protein kinase C phosphorylation sites, and does not show PMA-dependent changes in cellular localization (data not shown). Furthermore, PMA-stimulated activity is observed in the absence of Noxo1, suggesting that Noxa1, Rac1, or other upstream regulatory components are subject to PMA stimulation.

The effectiveness of Rac1 overexpression on Nox1 or Nox2 activity is dependent on the host cell line tested and the type of Rac1 mutant expressed. Mutant forms of Rac1 have little apparent effect on the fully reconstituted Nox1 system in HEK293 cells, although the same approach provided evidence for Rac1 involvement in the CHO-K1 cell model. HEK293 cells show significant accumulation of Rac1 in cortical regions and along the plasma membrane, even without stimulation, while CHO-K1 cells have a dispersed, but granular, cytoplas-

mic Rac1 staining pattern and exhibit a higher PMA-stimulated oxidase component. Thus, the effects of the overexpressed Rac1 mutants on the available Rac1 pools regulating oxidase activity may differ in the two cell lines. The Rac1(T17N) mutant does not affect Nox1 activity in any transfected cell line (data not shown), although Rac1(T17N) suppressed Nox2 activity in CHO-K1 cells but not in HEK293 cells (Fig. 3E). Overexpressed Rac1(G30S) is effective in suppressing both Nox1 (CHO-K1 cells) and Nox2 (HEK293 and CHO-K1 cells); moreover, Rac1(G30S) more effectively suppressed Nox2 activity than Rac1(T17N) in CHO-K1 cells (Fig. 3B and E). Previous work showed that Rac1(G30S) does not support the activity of the Nox2 complex *in vitro* (35, 49), and crystallographic data indicate that this residue forms direct hydrogen bonds with its effector, p67<sup>phox</sup> (37). Thus, Rac1(G30S) is a more effective “dominant-negative” mutant affecting Nox1 or Nox2 complexes than Rac1(T17N).

In agreement with recent reports (8, 15, 55), we found that Nox3 is distinctly different from Nox1 and Nox2, as it is more flexible in its requirements for classical (phox) or novel (Nox) supportive cofactors. Nox3 exhibits significant constitutive activity when expressed alone, but its activity is enhanced further in the presence of one or more supportive cofactors. We observed that Nox3 exhibits the following order of preference for modulators: p47<sup>phox</sup> plus p67<sup>phox</sup> > Noxo1 > p67<sup>phox</sup> > p47<sup>phox</sup> > Noxa1. Cheng et al. reported that Noxa1 slightly enhances Nox3 activity supported by Noxo1 (15), although we observed that Noxa1 inhibits Nox3 activity supported by Noxo1, consistent with observations by Ueno et al. in HEK293, CHO-K1, or Cos-7 cell models (55). Thus, Nox3 does not exhibit strict requirements for both an “activator” and “organizer” components. We have shown through mutagenesis of the “organizer” components that their ability to support Nox3 likely involves their interaction with p22<sup>phox</sup> and that Nox3 enables its transport to the plasma membrane. While the manuscript was in preparation, similar conclusions about the dependence of Nox3 on p22<sup>phox</sup> were described (55), based on the effects of p22<sup>phox</sup>, p47<sup>phox</sup>, and Noxo1 mutagenesis on Nox3 activity. However, Ueno et al. (55) concluded that Rac1 is not a regulator of Nox3, contrary to our current observations indicating that Rac1 regulates Nox3 activity.

Our evidence for Rac1 involvement in Nox3 activity includes the following: (i) Nox3 activity supported by p67<sup>phox</sup> or Noxa1 (whether wild type or the membrane-targeted forms) is inhibited by mutations in the Rac1 binding sites of these proteins; (ii) Nox3 activity alone, or that supported by Noxa1, is enhanced by coexpression of constitutively active Rac1(Q61L); (iii) siRNA-mediated suppression of cellular Rac1 production (with five different Rac1-targeted siRNAs) results in lower Nox3 activity when expressed in the contexts of the presence of p47<sup>phox</sup> and p67<sup>phox</sup>, p67<sup>phox</sup> alone, or Noxa1 alone or the absence of these cofactors. The siRNA-inhibited Nox3 activity, supported by p47<sup>phox</sup> and p67<sup>phox</sup>, was restored by transfection of wild-type Rac1. Finally, Nox3 activity supported by p47<sup>phox</sup> or Noxo1 alone was also enhanced by Rac1(Q61L), both in HEK293 and in CHO-K1 cells, and moderately inhibited (30 to 40%) by RNAi in the HEK293 cell model (both vector-based and synthetic Rac1-specific siRNAs; data not shown). Because Noxa1 inhibits Nox3 activity supported by Noxo1, we did not obtain evidence of Rac1 involvement in Nox3 regulation when

all three proteins were coexpressed, consistent with the findings of Ueno et al. (55). Indeed, any mutation that disrupts Noxa1 interactions with other oxidase components leads to enhanced Nox3 activity, which we attribute to the relief of its inhibitory effects on Nox3 and Noxo1 [i.e., Noxa1(R103E), Noxa1(W436R), Noxa1(R103E, W436R) (data not shown)]. We showed moderate inhibition of Nox3 activity supported by p47<sup>phox</sup> and p67<sup>phox</sup>(R102E) (without transfection of p22<sup>phox</sup>) in HEK293 and CHO-K1 cells, while Ueno et al. showed only slight inhibitory effects of p67<sup>phox</sup>(R102E) in Nox3 activity supported by overexpression of p22<sup>phox</sup>, p47<sup>phox</sup>, and p67<sup>phox</sup> in CHO-K1 cells. Ueno et al. (55) argued against involvement of Rac1 in the Nox3 system by showing that the dominant-negative [Rac1(T17N)] and constitutively active [Rac1(Q61L)] forms of Rac1 did not affect this enzyme reconstituted in CHO-K1 or HeLa cells, while these proteins did affect the Nox2-based systems. We were unable to enhance the activity of any Nox3 system in HEK293 cells that approached maximum levels by overexpression of constitutively active Rac1(Q61L) [i.e., Nox3 plus Noxa1(pp), Nox3 plus p67<sup>phox</sup>, and Nox3 plus p67<sup>phox</sup>(pp) (data not shown)]. However, Rac1(Q61L) does enhance the activity of Nox3 alone or Nox3 supported by Noxa1 alone in both HEK293 and CHO-K1 cells. Cheng et al. reported that the activity of Nox2 requires constitutively active Rac1(G12V) in HEK293H cells; on the other hand, Nox3 does not (15). Previous reports and the present study show that Nox1 does not require transfected active Rac1 to reconstitute the fully active system (14, 21, 54). Thus, it appears that Nox3 has a lower demand for Rac1, in comparison with Nox1 or Nox2, and that HEK293 cells have sufficient endogenous active Rac1 to support Nox3, even in the presence of the overexpressed mutants.

It is interesting that the phagocytic oxidase paradigm for the subcellular localization of phox regulators also applies to the Nox regulators, whereby Noxo1 targets Noxa1 to the plasma membrane, analogous to p47<sup>phox</sup> linking p67<sup>phox</sup> to the membrane. Our observations on the independent colocalization of Rac1 and Noxa1 or p67<sup>phox</sup> on membrane ruffles, when expressed in the absence of organizer proteins, may indicate that Rac1 acts together with these activators on other nonoxidase effectors at these subcellular sites. As noted above, the true physiological partners of Nox3 remain unclear, since differences across species were reported in the oxidase regulators detected in the inner ear; all four regulators have been detected in the mouse inner ear, where this oxidase has been implicated, while only p47<sup>phox</sup> and Noxa1 expression was detected in the rat inner ear (8, 13). Our clear demonstration of Rac1 regulation in concert with either “activator” component indicates that Nox3 has retained this functional property shared by Nox1 and Nox2. Our observations on Rac1 involvement in Nox3 in the absence of transfected “activators” raise the interesting possibilities that some other undefined Rac-dependent “activator” supports Nox3 or that Rac1 can interact directly with Nox3. Further studies are needed to appreciate the significance of Rac1-based regulation of Nox3 in a physiological context.

#### ACKNOWLEDGMENTS

We are grateful to Kristen Lekstrom for helpful comments about the manuscript.



This work was supported in part by grants to M.G. from the Hungarian Research Fund (OTKA 042573) and the Cystic Fibrosis Foundation. M.G. is a recipient of a Wellcome Trust International Senior Fellowship.

## REFERENCES

- Abo, A., E. Pick, A. Hall, N. Totty, C. G. Teahan, and A. W. Segal. 1991. Activation of the NADPH oxidase involves the small GTP-binding protein p21rac1. *Nature* **353**:668–670.
- Ago, T., T. Kitazono, J. Kuroda, Y. Kumai, M. Kamouchi, H. Ooboshi, M. Wakisaka, T. Kawahara, K. Rokutan, S. Ibayashi, and M. Iida. 2005. NAD(P)H oxidases in rat basilar arterial endothelial cells. *Stroke* **36**:1040–1046.
- Allou, N., Y. Gorzalczany, M. Itan, N. Sigal, and E. Pick. 2001. Activation of the superoxide-generating NADPH oxidase by chimeric proteins consisting of segments of the cytosolic component p67<sup>phox</sup> and the small GTPase Rac1. *Biochemistry* **40**:14557–14566.
- Ambasta, R. K., P. Kumar, K. K. Griendling, H. H. Schmidt, R. Busse, and R. P. Brandes. 2004. Direct interaction of the novel Nox proteins with p22<sup>phox</sup> is required for the formation of a functionally active NADPH oxidase. *J. Biol. Chem.* **279**:45935–45941.
- Ambruso, D. R., C. Knall, A. N. Abell, J. Panepinto, A. Kurkchubasche, G. Thurman, C. Gonzalez-Aller, A. Hiester, M. deBoer, R. J. Harbeck, R. Oyer, G. L. Johnson, and D. Roos. 2000. Human neutrophil immunodeficiency syndrome is associated with an inhibitory Rac2 mutation. *Proc. Natl. Acad. Sci. USA* **97**:4654–4659.
- Babior, B. M. 2004. NADPH oxidase. *Curr. Opin. Immunol.* **16**:42–47.
- Banfi, B., R. A. Clark, K. Steger, and K. H. Krause. 2003. Two novel proteins activate superoxide generation by the NADPH oxidase NOX1. *J. Biol. Chem.* **278**:3510–3513.
- Banfi, B., B. Malgrange, J. Knisz, K. Steger, M. Dubois-Dauphin, and K. H. Krause. 2004. NOX3, a superoxide-generating NADPH oxidase of the inner ear. *J. Biol. Chem.* **279**:46065–46072.
- Bokoch, G. M., B. P. Bohl, and T. H. Chuang. 1994. Guanine nucleotide exchange regulates membrane translocation of Rac/Rho GTP-binding proteins. *J. Biol. Chem.* **269**:31674–31679.
- Bokoch, G. M., and B. A. Diebold. 2002. Current molecular models for NADPH oxidase regulation by Rac GTPase. *Blood* **100**:2692–2695.
- Buul, J. D. V., M. Fernandez-Borja, E. C. Anthony, and P. L. Hordijk. 2005. Expression and localization of NOX2 and NOX4 in primary human endothelial cells. *Antioxid. Redox Signal.* **7**:308–317.
- Cheng, G., Z. Cao, X. Xu, E. G. V. Meir, and J. D. Lambeth. 2001. Homologs of gp91<sup>phox</sup>: cloning and tissue expression of Nox3, Nox4, and Nox5. *Gene* **269**:131–140.
- Cheng, G., and J. D. Lambeth. 2005. Alternative mRNA splice forms of NOX1: differential tissue expression and regulation of Nox1 and Nox3. *Gene* **356**:118–126.
- Cheng, G., and J. D. Lambeth. 2004. NOX1, regulation of lipid binding, localization, and activation of Nox1 by the Phox homology (PX) domain. *J. Biol. Chem.* **279**:4737–4742.
- Cheng, G., D. Ritsick, and J. D. Lambeth. 2004. Nox3 regulation by NOXO1, p47<sup>phox</sup>, and p67<sup>phox</sup>. *J. Biol. Chem.* **279**:34250–34255.
- Choy, E., V. K. Chiu, J. Silletti, M. Feoktistov, T. Morimoto, D. Michaelson, I. E. Ivanov, and M. R. Phillips. 1999. Endomembrane trafficking of Ras: the CAAX motif targets proteins to the ER and Golgi. *Cell* **98**:69–80.
- de Mendez, I., N. Homayounpour, and T. Leto. 1997. Specificity of p47<sup>phox</sup> SH3 domain interactions in NADPH oxidase assembly and activation. *Mol. Cell. Biol.* **17**:2177–2185.
- Freeman, J. L., and J. D. Lambeth. 1996. NADPH oxidase activity is independent of p47<sup>phox</sup> in vitro. *J. Biol. Chem.* **271**:22578–22582.
- Geiszt, M., K. Lekstrom, S. Brenner, S. M. Hewitt, R. Dana, H. L. Malech, and T. L. Leto. 2003. NAD(P)H oxidase 1, a product of a differentiated colon epithelial cells, can partially replace glycoprotein 91<sup>phox</sup> in the regulated production of superoxide by phagocytes. *J. Immunol.* **171**:299–306.
- Geiszt, M., K. Lekstrom, and T. L. Leto. 2004. Analysis of mRNA transcripts from the NAD(P)H oxidase 1 (Nox1) gene: evidence against production of the NADPH oxidase homolog-1 short (NOH-1S) transcript variant. *J. Biol. Chem.* **279**:51661–51668.
- Geiszt, M., K. Lekstrom, J. Witta, and T. L. Leto. 2003. Proteins homologous to p47<sup>phox</sup> and p67<sup>phox</sup> support superoxide production by NAD(P)H oxidase 1 in colon epithelial cells. *J. Biol. Chem.* **278**:20006–20012.
- Geiszt, M., and T. L. Leto. 2004. The Nox family of NAD(P)H oxidases: host defense and beyond. *J. Biol. Chem.* **279**:51715–51718.
- Gorzalcany, Y., N. Allou, N. Sigal, C. Weinbaum, and E. Pick. 2002. A prenylated p67<sup>phox</sup>-Rac1 chimera elicits NADPH-dependent superoxide production by phagocyte membranes in the absence of an activator and of p47<sup>phox</sup>. Conversion of a pagan NADPH oxidase to monotheism. *J. Biol. Chem.* **277**:18605–18610.
- Gorzalcany, Y., N. Sigal, M. Itan, O. Lotan, and E. Pick. 2000. Targeting of Rac1 to the phagocyte membrane is sufficient for the induction of NADPH oxidase assembly. *J. Biol. Chem.* **275**:40073–40081.
- Hanna, I. R., L. L. Hilenski, A. Dikalova, Y. Taniyama, S. Dikalov, A. Lyle, M. T. Quinn, B. Lassegue, and K. K. Griendling. 2004. Functional association of Nox1 with p22<sup>phox</sup> in vascular smooth muscle cells. *Free Radical Biol. Med.* **37**:1542–1549.
- Heyworth, P., B. Bohl, G. Bokoch, and J. Curnutte. 1994. Rac translocates independently of the neutrophil NADPH oxidase components p47<sup>phox</sup> and p67<sup>phox</sup>. Evidence for its interaction with flavocytochrome b<sub>558</sub>. *J. Biol. Chem.* **269**:30749–30752.
- Jesaitis, A. J., E. S. Buescher, D. Harrison, M. T. Quinn, C. A. Parkos, S. Livesey, and J. Linner. 1990. Ultrastructural localization of cytochrome b in the membranes of resting and phagocytosing human granulocytes. *J. Clin. Invest.* **85**:821–835.
- Kawahara, T., M. Kohjima, Y. Kuwano, H. Mino, S. Teshima-Kondo, R. Takeya, S. Tsunawaki, A. Wada, H. Sumimoto, and K. Rokutan. 2005. *Helicobacter pylori* lipopolysaccharide activates Rac1 and transcription of NADPH oxidase Nox1 and its organizer NOXO1 in guinea pig gastric mucosal cells. *Am. J. Physiol. Cell Physiol.* **288**:C450–C457.
- Kawahara, T., Y. Kuwano, S. Teshima-Kondo, R. Takeya, H. Sumimoto, K. Kishi, S. Tsunawaki, T. Hirayama, and K. Rokutan. 2004. Role of nicotinamide adenine dinucleotide phosphate oxidase 1 in oxidative burst response to Toll-like receptor 5 signaling in large intestinal epithelial cells. *J. Immunol.* **172**:3051–3058.
- Kawahara, T., D. Ritsick, G. Cheng, and J. D. Lambeth. 2005. Point mutations in the proline-rich region of p22<sup>phox</sup> are dominant inhibitors of Nox1 and Nox2-dependent reactive oxygen generation. *J. Biol. Chem.* **280**:31859–31869.
- Kikuchi, H., M. Hikage, H. Miyashita, and M. Fukumoto. 2000. NADPH oxidase subunit, gp91<sup>phox</sup> homologue, preferentially expressed in human colon epithelial cells. *Gene* **254**:237–243.
- Knaus, U. G., P. G. Heyworth, T. Evans, J. T. Curnutte, and G. M. Bokoch. 1991. Regulation of phagocyte oxygen radical production by the GTP-binding protein Rac 2. *Science* **254**:1512–1515.
- Koga, H., H. Terasawa, H. Nunoi, K. Takeshige, F. Inagaki, and H. Sumimoto. 1999. Tetratricopeptide repeat (TPR) motifs of p67<sup>phox</sup> participate in interaction with the small GTPase Rac and activation of the phagocyte NADPH oxidase. *J. Biol. Chem.* **274**:25051–25060.
- Koshkin, V., O. Lotan, and E. Pick. 1996. The cytosolic component p47<sup>phox</sup> is not a sine qua non participant in the activation of NADPH oxidase but is required for optimal superoxide production. *J. Biol. Chem.* **271**:30326–30329.
- Kwong, C. H., A. G. Adams, and T. L. Leto. 1995. Characterization of the effector-specifying domain of Rac involved in NADPH oxidase activation. *J. Biol. Chem.* **270**:19868–19872.
- Lambeth, J. D. 2004. NOX enzymes and the biology of reactive oxygen. *Nat. Rev. Immunol.* **4**:181–189.
- Lapouge, K., S. J. M. Smith, P. A. Walker, S. J. Gamblin, S. J. Smerdon, and K. Rittinger. 2000. Structure of the TPR domain of p67<sup>phox</sup> in complex with Rac.GTP. *Mol. Cell* **6**:899–907.
- Lassegue, B., D. Sorescu, K. Szocs, Q. Yin, M. Akers, Y. Zhang, S. L. Grant, J. D. Lambeth, and K. K. Griendling. 2001. Novel gp91<sup>phox</sup> homologues in vascular smooth muscle cells: nox1 mediates angiotensin II-induced superoxide formation and redox-sensitive signaling pathways. *Circ. Res.* **88**:888–894.
- Leto, T., M. Garrett, H. Fujii, and H. Nunoi. 1991. Characterization of neutrophil NADPH oxidase factors p47<sup>phox</sup> and p67<sup>phox</sup> from recombinant baculoviruses. *J. Biol. Chem.* **266**:19812–19818.
- Leto, T. L. 1999. The respiratory burst oxidase, p. 769–787. In J. I. Gallin and R. Snyderman (ed.), *Inflammation: basic principles and clinical correlates*. Lippincott Williams & Wilkins, Philadelphia, Pa.
- Leto, T. L., A. G. Adams, and I. de Mendez. 1994. Assembly of the phagocyte NADPH oxidase: binding of Src homology 3 domains to proline-rich targets. *Proc. Natl. Acad. Sci. USA* **91**:10650–10654.
- Miyano, K., S. Ogasawara, C. H. Han, H. Fukuda, and M. Tamura. 2001. A fusion protein between rac and p67<sup>phox</sup> (1–210) reconstitutes NADPH oxidase with higher activity and stability than the individual components. *Biochemistry* **40**:14089–14097.
- Nauseef, W. M. 2004. Assembly of the phagocyte NADPH oxidase. *Histochem. Cell Biol.* **122**:277–291.
- Nunoi, H., D. Rotrosen, J. I. Gallin, and H. L. Malech. 1988. Two forms of autosomal chronic granulomatous disease lack distinct neutrophil cytosol factors. *Science* **242**:1298–1301.
- Paffenholz, R., R. A. Bergstrom, F. Pasutto, P. Wabnitz, R. J. Munroe, W. Jagla, U. Heinzmann, A. Marquardt, A. Bareiss, J. Laufs, A. Russ, G. Stumm, J. C. Schimenti, and D. E. Bergstrom. 2004. Vestibular defects in head-tilt mice result from mutations in Nox3, encoding an NADPH oxidase. *Genes Dev.* **18**:486–491.
- Park, H. S., S. H. Lee, D. Park, J. S. Lee, S. H. Ryu, W. J. Lee, S. G. Rhee, and Y. S. Bae. 2004. Sequential activation of phosphatidylinositol 3-kinase, bPix, Rac1, and Nox1 in growth factor-induced production of H<sub>2</sub>O<sub>2</sub>. *Mol. Cell. Biol.* **24**:4384–4394.
- Pollock, J. D., D. A. Williams, M. A. Gifford, L. L. Li, X. Du, J. Fisherman, S. H. Orkin, C. M. Doerschuk, and M. C. Dinuer. 1995. Mouse model of

- X-linked chronic granulomatous disease, an inherited defect in phagocyte superoxide production. *Nat. Genet.* **9**:202–209.
48. Roberts, A. W., C. Kim, L. Zhen, J. B. Lowe, R. Kapur, B. Petryniak, A. Spaetti, J. D. Pollock, J. B. Borneo, G. B. Bradford, S. J. Atkinson, M. C. Dinauer, and D. A. Williams. 1999. Deficiency of the hematopoietic cell-specific Rho family GTPase Rac2 is characterized by abnormalities in neutrophil function and host defense. *Immunity* **10**:183–196.
  49. Sarfstein, R., Y. Gorzalcany, A. Mizrahi, Y. Berdichevsky, S. Molshanski-Mor, C. Weinbaum, M. Hirshberg, M.-C. Dagher, and E. Pick. 2004. Dual role of Rac in the assembly of NADPH oxidase, tethering to the membrane and activation of p67<sup>phox</sup>; a study based on mutagenesis of p67<sup>phox</sup>-Rac1 chimeras. *J. Biol. Chem.* **279**:16007–16016.
  50. Suh, Y. A., R. S. Arnold, B. Lassegue, J. Shi, X. Xu, D. Sorescu, A. B. Chung, K. K. Griendling, and J. D. Lambeth. 1999. Cell transformation by the superoxide-generating oxidase Mox1. *Nature* **401**:79–82.
  51. Sumimoto, H., K. Hata, K. Mizuki, T. Ito, Y. Kage, Y. Sakaki, Y. Fukumaki, M. Nakamura, and K. Takeshige. 1996. Assembly and activation of the phagocyte NADPH oxidase. Specific interaction of the N-terminal Src homology 3 domain of p47<sup>phox</sup> with p22<sup>phox</sup> is required for activation of the NADPH oxidase. *J. Biol. Chem.* **271**:22152–22158.
  52. Sumimoto, H., Y. Kage, H. Nunoi, H. Sasaki, T. Nose, Y. Fukumaki, M. Ohno, S. Minakami, and K. Takeshige. 1994. Role of Src homology 3 domains in assembly and activation of the phagocyte NADPH oxidase. *Proc. Natl. Acad. Sci. USA* **91**:5345–5349.
  53. Takeya, R., and H. Sumimoto. 2003. Molecular mechanism for activation of superoxide-producing NADPH oxidases. *Mol. Cells* **16**:271–277.
  54. Takeya, R., N. Ueno, K. Kami, M. Taura, M. Kohjima, T. Izaki, H. Nunoi, and H. Sumimoto. 2003. Novel human homologues of p47<sup>phox</sup> and p67<sup>phox</sup> participate in activation of superoxide-producing NADPH oxidases. *J. Biol. Chem.* **278**:25234–25246.
  55. Ueno, N., R. Takeya, K. Miyano, H. Kikuchi, and H. Sumimoto. 2005. The NADPH oxidase Nox3 constitutively produces superoxide in a p22<sup>phox</sup>-dependent manner: its regulation by oxidase organizers and activators. *J. Biol. Chem.* **280**:23328–23339.
  56. Ueyama, T., M. Eto, K. Kami, T. Tatsuno, T. Kobayashi, Y. Shirai, M. R. Lennartz, R. Takeya, H. Sumimoto, and N. Saito. 2005. Isoform-specific membrane targeting mechanism of Rac during FcγR-mediated phagocytosis: positive charge-dependent and independent targeting mechanism of Rac to the phagosome. *J. Immunol.* **175**:2381–2390.
  57. Verhoeven, A. J., B. G. Bolscher, L. J. Meerhof, R. van Zwieten, J. Keijer, R. S. Weening, and D. Roos. 1989. Characterization of two monoclonal antibodies against cytochrome b<sub>558</sub> of human neutrophils. *Blood* **73**:1686–1694.
  58. Yu, L., F. R. DeLeo, K. J. Biberstine-Kinkade, J. Renee, W. M. Nauseef, and M. C. Dinauer. 1999. Biosynthesis of flavocytochrome b<sub>558</sub>. gp91<sup>phox</sup> is synthesized as a 65-kDa precursor (p65) in the endoplasmic reticulum. *J. Biol. Chem.* **274**:4364–4369.
  59. Yu, L., L. Zhen, and M. C. Dinauer. 1997. Biosynthesis of the phagocyte NADPH oxidase cytochrome b<sub>558</sub>. Role of heme incorporation and heterodimer formation in maturation and stability of gp91<sup>phox</sup> and p22<sup>phox</sup> subunits. *J. Biol. Chem.* **272**:27288–27294.
  60. Zhao, T., V. Benard, B. P. Bohl, and G. M. Bokoch. 2003. The molecular basis for adhesion-mediated suppression of reactive oxygen species generation by human neutrophils. *J. Clin. Investig.* **112**:1732–1740.